Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.

NCT01768702 is registered in ClinicalTrials.gov with Celyad Oncology SA as lead sponsor.

NCT NCT01768702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01768702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.
Lead sponsor
Celyad Oncology SA
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2012
Completion date
August 31, 2017
Enrollment
315 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure